HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CTFA challenges FDA analysis of consumer AHA adverse events -- CIR meeting.

This article was originally published in The Rose Sheet

Executive Summary

CTFA DISPUTES FDA ANALYSIS OF CONSUMER AHA ADVERSE REACTION REPORTS at the March 5 meeting of the Cosmetic Ingredient Review Expert Panel in Washington, D.C. At the meeting, non-voting industry liaison Gerald McEwen, VP-science at the Cosmetic, Toiletry, and Fragrance Association, questioned the FDA statistic that for every cosmetic adverse reaction reported by a consumer to FDA, 50-100 are reported to manufacturers. "FDA has frequently over the years known things that I've been unable to find any validation for...this is probably one of those," McEwen asserted. "I submit the data does not support that," he concluded
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS002584

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel